According to a new analysis by the European Society of Cardiology, omega-3 supplements are associated with an increased likelihood of developing atrial fibrillation in people with high blood lipid levels.
The findings are published in the European Heart Journal – Cardiovascular Pharmacotherapy, a journal of the European Society of Cardiology (ESC).
The study’s author, Dr. Salvatore Carbone of the University of the British Commonwealth in Virginia, said: “Currently, fish oil supplements are indicated for patients with elevated plasma triglycerides to reduce cardiovascular risk.”
“Due to the high prevalence of elevated triglycerides in the population, they can often be prescribed. It should be noted that low doses of omega-3 fatty acids are available over the counter without a prescription.”
Some clinical studies suggest that omega-3 fatty acids may be associated with an increased risk of atrial fibrillation, the most common heart rhythm disorder. People with the disorder are five times more likely to have a stroke.
These studies tested different compositions of omega-3 fatty acids at different doses. Therefore, the authors performed a comprehensive meta-analysis of randomized controlled trials to answer the question of whether fish oils are consistently associated with an increased risk of atrial fibrillation.
The analysis included five randomized controlled trials examining the effects of omega-3 fatty acid supplements on cardiovascular outcomes.
Participants had elevated triglycerides and were either at high risk for cardiovascular disease or diagnosed with cardiovascular disease. A total of 50,277 patients received fish oil or placebo and were followed for between 2 and 7.4 years. The dose of fish oil varies from 0.84 g to 4 g per day.
The researchers found that the addition of omega-3 fatty acids was associated with a significantly increased risk of atrial fibrillation compared with placebo at a rate of 1.37 (95% confidence interval 1.22-1.54; p <0.001).
Dr Carbone said: “Our study suggests that fish oil supplements are associated with a significantly higher risk of atrial fibrillation in patients with an increased cardiovascular risk.”
“Although a clinical trial shows beneficial cardiovascular effects of supplements, the risk of atrial fibrillation should be considered when prescribing or buying such drugs on the stock exchange, especially in individuals prone to developing heart rhythm disorders,” he added. Carbon. (ANI)
This story was published by a telegraph agency show without changes in the text. Only the title has changed.